期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 160, 期 -, 页码 52-77出版社
ELSEVIER
DOI: 10.1016/j.addr.2020.10.001
关键词
Peptides; Self-assembly; Drug delivery; Blood-brain barrier; Transcytosis; Glioma; Alzheimer's disease; Parkinson's disease
资金
- ERC [MEViC 278793, CheSSTaG 769798]
- EPSRC/BTG Healthcare Partnership [EP/I001697/1]
- EPSRC Established Career Fellowship [EP/N026322/1]
- EPSRC/SomaNautix Healthcare Partnership [EP/R024723/1]
- CRUK City of London Centre
- Children with Cancer UK [16-227]
- Marie Sklodowska-Curie Actions
- EPSRC [EP/I001697/1, EP/N026322/1] Funding Source: UKRI
The targeted delivery of therapeutic compounds to the brain is arguably the most significant open problem in drug delivery today. Nanoparticles (NPs) based on peptides and designed using the emerging principles of molecular engineering show enormous promise in overcoming many of the barriers to brain delivery faced by NPs made of more traditional materials. However, shortcomings in our understanding of peptide self-assembly and blood-brain barrier (BBB) transport mechanisms pose significant obstacles to progress in this area. In this review, we discuss recent work in engineering peptide nanocarriers for the delivery of therapeutic compounds to the brain: from synthesis, to self-assembly, to in vivo studies, as well as discussing in detail the biological hurdles that a nanoparticle must overcome to reach the brain. (C) 2020 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据